AVGO vs CME Stock Comparison
Compare AVGO and CME across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between AVGO and CME?
AVGO and CME are close on the current AIQ evidence, so the better fit depends more on objective, risk tolerance and valuation preference than on a single headline score.
AlgovestIQ AIQ Comparison
Broadcom Inc. vs CME Group Inc.
AVGO and CME are effectively level
AVGO and CME are effectively level on the AIQ Score; the factor table below shows where each one holds its advantage.
Broadcom Inc.
CME Group Inc.
The Algovestiq AIQ Score does not currently separate AVGO and CME as of Sep 11, 2026. Both names are scored on the same 0–100 scale across Quality, Value, Momentum and Risk Resilience, and the factor table below shows where each one holds its advantage.
Compare Broadcom Inc. and CME Group Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare AVGO and CME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum39 vs 54CME +15
- Quality85 vs 74AVGO +11
- Value30 vs 26AVGO +4
- Risk Resilience52 vs 56CME +4
Neither name separates cleanly on the covered dimensions.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -3
No new signals fired.
Largest factor move: Momentum -5
No new signals fired.
Deeper signal detail for each name lives on its own signals page — AVGO and CME both carry a full feed there.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
EvenNeither separates on the overall score.
Growth
AVGOAVGO on combined revenue and EPS growth.
Value
AVGOAVGO on the peer-relative Value factor, by 4 points.
Momentum
CMECME on the Momentum factor, by 15 points.
Lower downside
CMECME on Risk Resilience, by 4 points.
Analyst upside
AVGOAVGO on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | AVGO | CME | Note |
|---|---|---|---|
| Implied upside to target | +39.4% | +14.9% | AVGO has more room |
| Target dispersion | +49.5% | +32.2% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 17 | 6 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
How each independent group of evidence reads the pair.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 52 vs 52 |
| Fundamentals | AVGOon balance | revenue growth 14.9% vs -9.2%; EPS growth 26.5% vs -12%; TTM ROE 36.4% vs 15.5%; gross margin 67% vs 81.9%; operating margin 43.7% vs 65.1% — AVGO takes 3 of 5 decided legs, not all of them |
| Valuation | AVGO | Value 30 vs 26 |
| Technicals | CME | Price vs 50-day -5.5% vs 5.3%; vs 200-day -2.5% vs -1.7% |
| Risk Resilience | CME | Risk Resilience 52 vs 56 |
| Analyst expectations | AVGO | Target upside 39.4% vs 14.9% |
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 0 points. (argues the conclusion is provisional)
- Only 1 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
How the comparison changed
119 daily snapshots · May 4 – Sep 10CME lead: Weakening — the AIQ differential moved from 8 to 0 points over 30 sessions.
- Today
- Level
- 52 vs 52
- 7 sessions ago
- CME +10
- 47 vs 57
- 30 sessions ago
- CME +8
- 45 vs 53
- 90 sessions ago
- AVGO +5
- 50 vs 45
The lead changed hands 7 times in this window, most recently on Aug 18 when CME moved ahead of AVGO.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (3.55%)
- MACD Bearish Crossover — bearish, momentum, short horizon
0 bullish / 2 bearish
- Death Cross Active — bearish, trend, long horizon (6.50%)
- MACD Bearish Crossover — bearish, momentum, short horizon
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.32%, AIQ -1 points).
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.54%, AIQ -1 points).
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
AVGO leads on balance| Metric | AVGO | CME |
|---|---|---|
| Revenue growth (YoY) | 14.9% | -9.2% |
| EPS growth (YoY) | 26.5% | -12% |
| Gross margin | 67% | 81.9% |
| Operating margin | 43.7% | 65.1% |
| Return on equity (TTM) | 36.4% | 15.5% |
| Debt to equity | 0.74 | 0.13 |
Performance
Split across windows| Metric | AVGO | CME |
|---|---|---|
| 1 week (5 sessions) | -1.7% | -1.3% |
| 1 month (20 sessions) | -13.3% | 4.5% |
| 3 months (63 sessions) | -3% | 3.9% |
| 6 months (126 sessions) | 5.6% | -9.6% |
| Year to date | 4.3% | 0.4% |
| 1 year (252 sessions) | 6.9% | 4.4% |
Technicals
CME has the stronger structure| Metric | AVGO | CME |
|---|---|---|
| RSI (14) | 47.7 | 53.9 |
| ADX (14) | 23.4 | 22.7 |
| Price vs 50-day | -5.5% | 5.3% |
| Price vs 200-day | -2.5% | -1.7% |
| Volatility (1M, annualized) | 37.6% | 21.7% |
Risk
CME is the more resilient| Metric | AVGO | CME |
|---|---|---|
| Beta | 2.16 | -0.32 |
| Sharpe ratio | 0.3 | 0.15 |
| Sortino ratio | 0.44 | 0.21 |
| Max drawdown | -28.9% | -33% |
| Current drawdown | -25.1% | -16.1% |
| Annualized volatility | 47.5% | 23.9% |
| Value at risk (95%) | -4.4% | -2.8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which has more analyst upside, AVGO or CME?
Analyst price targets imply +39.4% upside for AVGO and +14.9% for CME, so the Street currently favors AVGO. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AVGO or CME?
AVGO is the better-valued of the two on the peer-relative Value factor. AVGO on the peer-relative Value factor, by 4 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AVGO or CME?
AVGO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AVGO or CME?
CME on the Momentum factor, by 15 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AVGO or CME?
CME is the more resilient of the two, so the other name carries the higher downside risk. CME on Risk Resilience, by 4 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AVGO more profitable than CME?
The profitability evidence is mixed: gross margin 67% vs 81.9%; operating margin 43.7% vs 65.1%; ttm roe 36.4% vs 15.5%. AVGO leads on one measure and CME on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
What do the current signals say about AVGO and CME?
AVGO: 1 bullish / 1 bearish, conflicted. CME: 0 bullish / 2 bearish. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AVGO is Golden Cross Active (bullish, long horizon). On CME it is Death Cross Active (bearish, long horizon).
Compare AVGO and CME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.